A Study of Pembrolizumab With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study’s 2 primary hypotheses are: Pembrolizumab plus maintenance